Exelixis, Inc.
$46.57
▲
1.48%
2026-04-22 10:12:13
www.exelixis.com
NMS: EXEL
Explore Exelixis, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$11.84 B
Current Price
$46.57
52W High / Low
$49.62 / $33.76
Stock P/E
16.78
Book Value
$8.23
Dividend Yield
—
ROCE
36.6%
ROE
35.53%
Face Value
—
EPS
$2.78
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
1,077
Beta
0.42
Debt / Equity
9.3
Current Ratio
3.56
Quick Ratio
3.5
Forward P/E
11.31
Price / Sales
5.12
Enterprise Value
$10.64 B
EV / EBITDA
11.54
EV / Revenue
4.59
Rating
Buy
Target Price
$46.83
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Fortrea Holdings Inc. | $10.44 | — | $976.14 M | — | -1.7% | -1.02% | $18.67 / $3.97 | $6.05 |
| 2. | Alector, Inc. | $2.71 | — | $298.53 M | — | -69.73% | -1.82% | $3.4 / $0.9 | $0.28 |
| 3. | Coya Therapeutics, Inc. | $4.99 | — | $112.13 M | — | -51.17% | -51.39% | $7.75 / $3.71 | $2.06 |
| 4. | IO Biotech, Inc. | $0.01 | — | $0.55 M | — | -197.41% | -2.4% | $2.79 / $0.01 | $0.01 |
| 5. | NeuroSense Therapeutics Ltd. | $0.71 | — | $25.1 M | — | -383.35% | -21.75% | $2.6 / $0.63 | $-0.05 |
| 6. | MediWound Ltd. | $17.35 | — | $226.34 M | — | -41.75% | -63.86% | $22.5 / $14.9 | $3.4 |
| 7. | Ionis Pharmaceuticals, Inc. | $74.84 | — | $12.38 B | — | -13.92% | -70.8% | $86.74 / $27.9 | $3 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 598.66 M | 597.75 M | 568.26 M | 555.45 M | 566.75 M | — |
| Operating Profit | 235.91 M | 256.36 M | 213.58 M | 186.86 M | 163.46 M | — |
| Net Profit | 244.53 M | 193.58 M | 184.85 M | 159.62 M | 139.86 M | — |
| EPS in Rs | 0.94 | 0.75 | 0.71 | 0.61 | 0.54 | 0.4 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.32 B | 2.17 B | 1.83 B | 1.61 B |
| Operating Profit | 892.7 M | 689.95 M | 170.88 M | 201.48 M |
| Net Profit | 782.57 M | 521.27 M | 207.76 M | 182.28 M |
| EPS in Rs | 3.01 | 2.01 | 0.8 | 0.7 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.84 B | 2.95 B | 2.94 B | 3.07 B |
| Total Liabilities | 683.1 M | 703.49 M | 678.45 M | 583.06 M |
| Equity | 2.16 B | 2.24 B | 2.26 B | 2.49 B |
| Current Assets | 1.44 B | 1.47 B | 1.32 B | 1.62 B |
| Current Liabilities | 405.64 M | 403.77 M | 394.28 M | 324.36 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 884.27 M | 699.97 M | 333.32 M | 362.61 M |
| Investing CF | 350.44 M | -116.78 M | -26.95 M | -524.41 M |
| Financing CF | -969.59 M | -628.81 M | -546.05 M | 0.59 M |
| Free CF | 844.34 M | 633.79 M | 170.35 M | 224.16 M |
| Capex | -39.93 M | -66.19 M | -162.97 M | -138.46 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 6.98% | 18.49% | 13.6% | — |
| Earnings Growth % | 50.13% | 150.89% | 13.98% | — |
| Profit Margin % | 33.73% | 24.04% | 11.35% | 11.31% |
| Operating Margin % | 38.48% | 31.81% | 9.34% | 12.51% |
| Gross Margin % | 96.39% | 96.49% | 96.04% | 96.41% |
| EBITDA Margin % | 39.73% | 33.14% | 10.74% | 13.8% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.